Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College

Rhea-AI Summary

ChromaDex Corp. (NASDAQ: CDXC) announced a significant legal victory as the U.S. Patent Trial and Appeal Board rejected Thorne Research's attempt to invalidate U.S. Patent No. 8,197,807, exclusively licensed for compositions containing nicotinamide riboside (NR). This decision strengthens ChromaDex's position in a patent infringement lawsuit against Thorne Research. The company is known for its flagship ingredient, Niagen®, which is backed by extensive clinical research and approved by leading global regulatory agencies.

Positive

• Successful legal ruling affirming ChromaDex's patent on nicotinamide riboside strengthens market position.
• ChromaDex's Niagen® has 20 published clinical trials supporting its efficacy.
• The company maintains over 40 patents related to NR, enhancing its intellectual property portfolio.

Negative

• None.

The “807” patent held under exclusive license covers compositions comprising NAD+ precursor nicotinamide riboside

LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office’s Patent Trial and Appeal Board’s (“PTAB”) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (“the 807 patent”). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne Research, Inc. from raising these arguments, or any other arguments they could have reasonably raised before the PTAB in the New York District Court lawsuit ChromaDex brought against Thorne Research, Inc. wherein ChromaDex alleges Thorne Research, Inc. is infringing the 807 patent.

ChromaDex is the exclusive supplier of nicotinamide riboside chloride, Niagen®, a novel form of NR backed by 20 published and peer-reviewed clinical trials. Niagen® has achieved regulatory acceptance by the world’s four leading regulatory bodies including the U.S. FDA, Health Canada, the European Commission, and the Therapeutic Goods Administration (TGA) of Australia.

ChromaDex maintains a strong and growing intellectual property portfolio for its proprietary ingredient, Niagen®, including for use in supplements and foods, consisting of over 40 composition, process, and method of use patents for discoveries relating to NR and other precursors to NAD⁺ (nicotinamide adenine dinucleotide), a molecule at the forefront of healthy aging and cellular health.

For additional information about ChromaDex, please visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the PTAB proceedings and the impact of those proceedings. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220815005235/en/

ChromaDex Media Contact:

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact:

Tom Shumaker, LifeSci Advisors, Managing Director

917-929-7600

tshumaker@lifesciadvisors.com

Source: ChromaDex Corporation

FAQ

What was the recent legal decision involving ChromaDex (CDXC)?

The U.S. Patent Trial and Appeal Board rejected Thorne Research's attempt to invalidate ChromaDex's U.S. Patent No. 8,197,807.

How does the ruling affect ChromaDex's business?

The ruling strengthens ChromaDex's position in a patent infringement lawsuit against Thorne Research and protects its proprietary product, Niagen®.

What is nicotinamide riboside and why is it significant to ChromaDex (CDXC)?

Nicotinamide riboside is a precursor to NAD+, and is significant for ChromaDex as it is the main ingredient in their product Niagen®, which supports healthy aging.

What regulatory approvals does Niagen® have?

Niagen® has achieved regulatory acceptance from the U.S. FDA, Health Canada, the European Commission, and Australia's TGA.